Literature DB >> 20689563

Multiple sclerosis: monitoring long-term treatments in multiple sclerosis.

Massimo Filippi, Maria A Rocca.   

Abstract

Patients with relapsing-remitting multiple sclerosis have been shown to benefit from disease-modifying treatments over prolonged periods. More focus should now be placed on monitoring the long-term evolution of this disease (making use of tools such as MRI), alongside the patients' response and adherence to such treatments.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20689563     DOI： 10.1038/nrneurol.2010.88

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group.

Authors:  Sheila A Doggrell
Journal:  Expert Opin Pharmacother       Date:  2010-05       Impact factor: 3.889

2.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Authors:  Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

3.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

4.  Gray matter atrophy is related to long-term disability in multiple sclerosis.

Authors:  Leonora K Fisniku; Declan T Chard; Jonathan S Jackson; Valerie M Anderson; Daniel R Altmann; Katherine A Miszkiel; Alan J Thompson; David H Miller
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

Review 5.  Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

Authors:  Oleksandra Katrych; Tessa M Simone; Shara Azad; Shaker A Mousa
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 6.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Authors:  Frederik Barkhof; Peter A Calabresi; David H Miller; Stephen C Reingold
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

Review 7.  MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.

Authors:  M Rovaris; F Barkhof; M Calabrese; N De Stefano; F Fazekas; D H Miller; X Montalban; C Polman; M A Rocca; A J Thompson; T A Yousry; M Filippi
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

8.  New natural history of interferon-beta-treated relapsing multiple sclerosis.

Authors:  Maria Trojano; Fabio Pellegrini; Aurora Fuiani; Damiano Paolicelli; Valentina Zipoli; Giovanni B Zimatore; Elisabetta Di Monte; Emilio Portaccio; Vito Lepore; Paolo Livrea; Maria Pia Amato
Journal:  Ann Neurol       Date:  2007-04       Impact factor: 10.422

9.  How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Authors:  M G Brown; S Kirby; C Skedgel; J D Fisk; T J Murray; V Bhan; I S Sketris
Journal:  Neurology       Date:  2007-08-15       Impact factor: 9.910

10.  Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Authors:  C Ford; A D Goodman; K Johnson; N Kachuck; J W Lindsey; R Lisak; C Luzzio; L Myers; H Panitch; J Preiningerova; A Pruitt; J Rose; H Rus; J Wolinsky
Journal:  Mult Scler       Date:  2010-01-27       Impact factor: 6.312
  10 in total
  1 in total

1.  Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.

Authors:  Deepak M W Balak; Gerald J D Hengstman; Enes Hajdarbegovic; Rob J P van den Brule; Raymond M M Hupperts; Hok Bing Thio
Journal:  BMC Neurol       Date:  2013-10-16       Impact factor: 2.474
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.